ETHYL 5-[(2,3-DIOXO-2,3-DIHYDRO-1H-INDOL-1-YL)METHYL]-2-FUROATE | 312590-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ETHYL 5-[(2,3-DIOXO-2,3-DIHYDRO-1H-INDOL-1-YL)METHYL]-2-FUROATE
• 英文别名: ethyl 5-[(2,3-dioxoindol-1-yl)methyl]furan-2-carboxylate
• CAS: 312590-25-3
• 化学式: C₁₆H₁₃NO₅
• 分子量: 299.283
• InChiKey: GNDDLIUNUBKDQG-UHFFFAOYSA-N

物化性质

• 沸点：
  487.9±55.0 °C(Predicted)
• 密度：
  1.372±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  76.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ETHYL 5-[(2,3-DIOXO-2,3-DIHYDRO-1H-INDOL-1-YL)METHYL]-2-FUROATE 在 溶剂黄146 作用下， 以 三氟乙酸 、 苯 为溶剂， 反应 2.5h， 生成 5-[2-(4-Methoxy-phenyl)-1,3a,4,9,10-pentaaza-cyclopenta[b]fluoren-9-ylmethyl]-furan-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  1,2-二氨基咪唑与靛红的缩合

  摘要：

  DOI：

  10.1515/hc.2002.8.6.537
• 作为产物：
  描述：

  5-氯甲基-2-呋喃甲酸乙酯 在 NaH 作用下， 以 1,4-二氧六环 、 正己烷 、 乙酸乙酯 为溶剂， 以19%的产率得到ETHYL 5-[(2,3-DIOXO-2,3-DIHYDRO-1H-INDOL-1-YL)METHYL]-2-FUROATE
  参考文献：
  名称：

  GAL3 receptor antagonists for the treatment of affective disorders

  摘要：

  这项发明涉及选择性拮抗剂对GAL3受体的嘧啶和吲哚酮衍生物。该发明提供了一种治疗患有情感障碍的受试者的方法，包括向受试者施用一定量的该发明化合物，以有效治疗受试者的情感障碍。该发明还提供了一种治疗受试者情感障碍的方法，包括向受试者施用包含药用可接受载体和治疗有效量GAL3受体拮抗剂的组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药用可接受载体。

  公开号：

  US20040110821A1

文献信息

• Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
  申请人：——

  公开号：US20030078271A1

  公开（公告）日：2003-04-24

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及嘧啶和吲哚酮衍生物，它们是选择性GAL3受体拮抗剂。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。该发明还提供了通过结合该发明化合物的治疗有效量和药用载体制备的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药用载体。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用足以治疗受试者抑郁症和/或焦虑症的该发明化合物的量。该发明还提供了一种治疗受试者抑郁症和/或焦虑症的方法，包括向受试者施用包含药用载体和治疗有效量GAL3受体拮抗剂的组合物。
• Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
  申请人：——

  公开号：US20040102507A1

  公开（公告）日：2004-05-27

  This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.

  这项发明涉及对GALR3受体的拮抗剂，即吲哚酮衍生物。该发明提供了一种包含本发明化合物的治疗有效量和药用可接受载体的药物组合物。此外，该发明还提供了一种由结合本发明化合物的治疗有效量和药用可接受载体制成的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药用可接受载体。
• GAL3 receptor antagonists for the treatment of affective disorders
  申请人：——

  公开号：US20040110821A1

  公开（公告）日：2004-06-10

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. This invention provides a method of treating a subject suffering from an affective disorder which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's affective disorder. This invention also provides a method of treating an affective disorder in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.

  这项发明涉及选择性拮抗剂对GAL3受体的嘧啶和吲哚酮衍生物。该发明提供了一种治疗患有情感障碍的受试者的方法，包括向受试者施用一定量的该发明化合物，以有效治疗受试者的情感障碍。该发明还提供了一种治疗受试者情感障碍的方法，包括向受试者施用包含药用可接受载体和治疗有效量GAL3受体拮抗剂的组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药用可接受载体。
• Use of GAL3 antagonist for treatment of depression
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20040127502A1

  公开（公告）日：2004-07-01

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  本发明涉及嘧啶和吲哚酮衍生物，它们是选择性GAL3受体拮抗剂。本发明提供一种包含本发明化合物的治疗有效量和药学上可接受的载体的制药组合物。本发明还提供一种由本发明化合物的治疗有效量和药学上可接受的载体组合而成的制药组合物。本发明还提供一种制备包括本发明化合物的治疗有效量和药学上可接受的载体的制药组合物的方法。本发明还提供一种治疗患有抑郁症和/或焦虑症的受试者的方法，该方法包括向受试者施用本发明化合物的治疗有效量以治疗受试者的抑郁症和/或焦虑症。本发明还提供一种治疗受试者抑郁症和/或焦虑症的方法，该方法包括向受试者施用一种包含药学上可接受的载体和GAL3受体拮抗剂的治疗有效量的组合物。
• Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods
  申请人：Blackburn P. Thomas

  公开号：US20070259942A1

  公开（公告）日：2007-11-08

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及选择性拮抗GAL3受体的嘧啶和吲哚酮衍生物。该发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组合而成的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。该发明还提供了一种治疗患有抑郁和/或焦虑的受试者的方法，包括向受试者投予本发明化合物的治疗有效量。该发明还提供了一种治疗受试者抑郁和/或焦虑的方法，包括向受试者投予一种药学上可接受的载体和治疗有效量的GAL3受体拮抗剂的组合物。